Wuhan Binhui Biotechnology Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2010

Location

Wuhan Hubei China

Primary Industry

Biotechnology

About

Established in 2010 and based in Wuhan, China, BinHui Biotech operates as a biomedical company that focuses on the oncolytic virus immunotherapy field. The company's founder and chairman, Binlei Liu, has a PhD in molecular viruses from the University of Southampton in the UK, and has more than 20 years of experience in tumor immunity and lysosomal virus research. It has partnerships with Atagenix, Hong Tough Pharmaceuticals and Sugar Smart Pharmaceuticals. In April 2024, it closed a strategic funding. The company developed oHSV2 that monotherapy kills tumor cells directly and activates immune response through specific targeting and replication based on oncoytic virus platform. The company also developed recombinant protein vaccine, and nucleic acid vaccine, based on the vaccine R&D platform. Its first product has obtained three Investigational New Drug (IND) approvals for OV mono and combo therapies. Also, in August 2021, the BS001(OH2) injection was approved by the Food and Drug Administration (FDA) for the clinical trial of various indications in the US, such as esophageal cancer, melanoma, glioblastoma. The company generates revenue by advancing its innovative oncolytic virus drugs through clinical trials and towards commercialization. The company will use the strategic funding to advance core pipeline clinical trials and lysosomal virus drug development.

Current Investors

Lepu Medical Technology (Beijing) Co., Ltd, Lapam Capital, Temasek Holdings

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.binhui-bio.com.cn

Verticals

Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.